+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Influence of Chlamydia pneumoniae and cytomegalovirus infections on prevalence and the course of coronary artery disease

Influence of Chlamydia pneumoniae and cytomegalovirus infections on prevalence and the course of coronary artery disease

Polskie Archiwum Medycyny Wewnetrznej 105(1): 39-44

Chlamydia pneumoniae (C. pneumoniae) as well as cytomegalovirus (CMV) are common pathogens found in about 50% of healthy western population. Many studies suggest a role of C. pneumoniae in development of coronary artery disease (CAD). CMV infection is also considered to increase risk of developing of CAD as well as restenosis after percutaneous coronary revascularization (PCI). The aim of our study was to evaluate a possible role of C. pneumoniae and CMV infections in both CAD development and course in patients (pts) undergoing PTCA. We enrolled 105 pts (mean age 56.4 years, 83 males) with angiographically documented CAD. Control group consisted of 63 healthy controls (mean age 47.25 years; 31 males). The study subjects were evaluated for presence of C. pneumoniae specific IgG antibodies (MIF test--MRL Diagnostic, USA; seroprevalence assumed when titre > or = 1/8). In 58 random PCI pts CMV specific IgG antibodies (ELISA Eti-Cytok-G PLUS--Dia Sorin) were evaluated. Pts were sampled at the time of PTCA. All PCI pts were assessed by angina questionnaire 5.9 +/- 2.6 months (mo) after the procedure with respect to clinical restenosis. C. pneumoniae IgG antibodies were detected in 37.1% of pts and in 22% of healthy controls (p < 0.05). After logistic regression was applied trend towards more frequent occurrence of C. pneumoniae specific IgG in CAD pts was shown (p = 0.10 OR = 2.4; 95% CI: 0.8-6.8). No significant correlation was found between anti-C. pneumoniae IgG presence or anti-CMV IgG titre and coronary atherosclerosis advancement. There was no significant difference in anti-CMV IgG titre between 9 pts who developed clinical restenosis 5.9 +/- 2.6 mo after PCI and the remaining pts. Our study results suggest a possible significant correlation between C. pneumoniae with CAD prevalence. We did not find a positive association of either infection markers with coronary atherosclerosis advancement. We did not find correlation of clinical restenosis after PCI with markers of CMV infection.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 046395328

Download citation: RISBibTeXText

PMID: 11505697

Related references

A role of Chlamydia pneumoniae and cytomegalovirus infections in coronary artery disease in Polish population. European Heart Journal 20(ABSTR Suppl. ): 425, 1999

Prevalence of Helicobacter pylori, cytomegalovirus, and Chlamydia pneumoniae immunoglobulin seropositivity in coronary artery disease patients and normal individuals in North Indian population. Medical Journal Armed Forces India 68(1): 53-57, 2012

H pylori, Chlamydia pneumoniae or cytomegalovirus infection and coronary artery disease. Helicobacter 8(4): 448, 2003

Role of Chlamydia pneumoniae, helicobacter pylori and cytomegalovirus in coronary artery disease. Pakistan Journal of Pharmaceutical Sciences 24(2): 95, 2011

Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus: Chronic infections and coronary heart disease. Pharmacotherapy 20(1): 52-63, 2000

Association of serology with the endovascular presence of Chlamydia pneumoniae and Cytomegalovirus in coronary artery and vein graft disease. Circulation 100(18 Suppl. ): I 599, 1999

The prevalence of Chlamydia pneumoniae antibodies in Thai patients with coronary artery disease. Journal of the Medical Association of Thailand 82(8): 792-797, 1999

Prevalence of Chlamydia pneumoniae IgG antibodies in patients with coronary artery disease: a report from an Indian population. Indian Heart Journal 55(6): 667-667, 2004

High prevalence of IgG antibody to Chlamydia pneumoniae in patients with proven coronary artery disease in a western Galilee population. European Heart Journal 20(ABSTR Suppl. ): 424, 1999

Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 99(12): 1540-1547, 1999

Prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae in different forms of coronary disease. Arquivos Brasileiros de Cardiologia 92(6): 405, 2009

Detection of Chlamydia pneumoniae but not cytomegalovirus in occluded saphenous vein coronary-artery bypass grafts. Circulation 98(17 Suppl. ): I408, 1998

Presence of cytomegalovirus, and Chlamydia pneumoniae in coronary atherosclerotic lesions Distribution patterns, co-infections, and clinical findings. Circulation 100(18 Suppl. ): I 579, 1999

Antibodies to cytomegalovirus or Chlamydia pneumoniae and coronary heart disease. Lancet 351(9096): 142; Author Reply 143, 1998